Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

KDM6A controls immunogenicity in MM

Jerome Moreaux

Blood (2024) 144 (14): 1465–1467.

https://doi.org/10.1182/blood.2024026013

Published: 2024

Journal Articles

Integrative single-cell chromatin and transcriptome analysis of human plasma cell differentiation

Elina Alaterre, Sara Ovejero, Caroline Bret, Laure Dutrieux, Dassou Sika, Raul Fernandez Perez, Marion Espéli, Thierry Fest, Michel Cogné, José Ignacio Martin-Subero, Pierre Milpied, Giacomo Cavalli, Jérôme Moreaux

Blood (2024) 144 (5): 496–509.

https://doi.org/10.1182/blood.2023023237

Published: 2024

Includes: Supplemental data

Journal Articles

Integrative Multi-Omics Analysis of Tumor-Immune Microenvironment in Multiple Myeloma: Novel Insights and Therapeutic Implications

Elina Alaterre, Nicolas Robert, Guilhem Requirand, Amélie Machura, Hugues De Boussac, Laure Vincent, Charles Herbaux, Angélique Bruyer, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2023-181767

Published: 2023

Journal Articles

Integrative Single-Cell RNA-Seq and Single-Cell ATAC-Seq Analysis of Human Plasma Cell Differentiation

Elina Alaterre, Sara Ovejero, Marion Espéli, Thierry Fest, Michel Cogné, Pierre Milpied, Giacomo Cavalli, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 86.

https://doi.org/10.1182/blood-2023-181507

Published: 2023

Journal Articles

Epigenetic Modifiers MMSET and EZH2 Physically Interact and Cooperate to Support Multiple Myeloma Pathophysiology

Emmanuel Varlet, Elina Alaterre, Morgane Thomas, Hugues De Boussac, Laure Vincent, Guillaume Cartron, Charles Herbaux, Caroline Bret, Laurie Herviou, Anne Marie Martinez, Christophe Hirtz, Aurore Attina, Jerome Vialaret, Giacomo Cavalli, Jerome Moreaux, Sara Ovejero

Blood (2023) 142 (Supplement 1): 1964.

https://doi.org/10.1182/blood-2023-181018

Published: 2023

Journal Articles

Characterization of a New Metabolic Score Correlated with CD38 Cell-Surface Expression and Response to Daratumumab Treatment in Multiple Myeloma

Alizée Steer, Elina Alaterre, Djamila Chamlal, Emmanuel Varlet, Amélie Machura, Alboukadel Kassambara, Guilhem Requirand, Nicolas Robert, Laure Vincent, Charles Herbaux, Hugues De Boussac, Angélique Bruyer, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2023-180877

Published: 2023

Journal Articles

Translation Inhibition through eIF4A1 Targeting in Multiple Myeloma Is a Promising Therapeutic Strategy

Laure Dutrieux, Elle Loughran, Armelle Choquet, Hélène Herault, Antoine Guillemin, Nicolas Robert, Guilhem Requirand, Guillaume Cartron, Laure Vincent, Charles Herbaux, Eric Rivals, Alexandre David, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2023-184749

Published: 2023

Journal Articles

Lipid-Mediated Modulation of DNA Damage Signaling As a Prognostic and Therapeutic Strategy Against Multiple Myeloma

Elvira Garcia De Paco, Caroline Soulet, Guilhem Requirand, Nicolas Robert, Guillaume Cartron, Laure Vincent, Charles Herbaux, Maria Moriel-Carretero, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 3322.

https://doi.org/10.1182/blood-2023-181039

Published: 2023

Journal Articles

Early Progressions of Undetermined Significance (EPUS) in the Month Following CAR-T Cells for B-Cell NHL Is Mainly Related to Pseudoprogression

Benoît Tisserand, Caroline Bret, Yassine Al Tabaa, Sylvain Lamure, Xavier Ayrignac, Laura Platon, Patrice Ceballos, Ludovic Gabellier, Jerome Moreaux, Charles Herbaux, Guillaume Cartron, Jean-Jacques Tudesq

Blood (2023) 142 (Supplement 1): 3124.

https://doi.org/10.1182/blood-2023-185520

Published: 2023

Journal Articles

Ironomycin Induces Mantle Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Sara ovejero-Merino, Laura Alibert, Julie Devin, Tatiana Cañeque, Ouissem Karmous Gadacha, Matthieu Abouladze, Guilhem Requirand, Nicolas Robert, Hugues De Boussac, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Jerome Moreaux, Caroline Bret

Blood (2022) 140 (Supplement 1): 6439–6440.

https://doi.org/10.1182/blood-2022-164644

Published: 2022

Journal Articles

Targeting Iron Homeostasis As a Therapeutic Strategy in Multiple Myeloma

Sara ovejero-Merino, Julie Devin, Tatiana Cañeque, Laura Alibert, Guilhem Requirand, Nicolas Robert, Alizée Steer, Amelie Machura, Christophe Hirtz, Angélique Bruyer, Laure Vincent, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Caroline Bret, Jerome Moreaux

Blood (2022) 140 (Supplement 1): 9980–9981.

https://doi.org/10.1182/blood-2022-163252

Published: 2022

Journal Articles

EZH2 Targeting Induces CD38 Upregulation and Response to Anti-CD38 Antibodies in Multiple Myeloma

Djamila Chemlal, Emmanuel Varlet, Amelie Machura, Guilhem Requirand, Nicolas Robert, Elina Alaterre, Laure Vincent, Charles Herbaux, Giacomo Cavalli, Angélique Bruyer, Hugues De Boussac, Jerome Moreaux

Blood (2022) 140 (Supplement 1): 4220–4221.

https://doi.org/10.1182/blood-2022-163261

Published: 2022

Journal Articles

Development of a Robust BH3 Profiling Toolkit for Precision Medicine in Hematologic Malignancies

Valentin Jacquier, Antoine Guillemin, Sara Ovejero-Merino, Guilhem Requirand, Ouissem Karmous-Gadacha, Laure Dutrieux, Andrea Romero, Alizée Steer, Amelie Machura, Hugues De Boussac, Jerome Moreaux, Charles Herbaux

Blood (2022) 140 (Supplement 1): 10727–10728.

https://doi.org/10.1182/blood-2022-163207

Published: 2022

Journal Articles

PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma

Marion Haas, Gersende Caron, Fabrice Chatonnet, Stéphane Manenti, Elina Alaterre, Julie Devin, Céline Delaloy, Giulia Bertolin, Roselyne Viel, Amandine Pignarre, Francisco Llamas-Gutierrez, Anne Marchalot, Olivier Decaux, Karin Tarte, Laurent Delpy, Jérôme Moreaux, Thierry Fest

Blood (2022) 139 (15): 2316–2337.

https://doi.org/10.1182/blood.2021014011

Published: 2022

Includes: Supplemental data

Journal Articles

Genomic Characterization of in Vitro Acquired-Resistance to Proteasome Inhibitors

Hugues De Boussac, Alboukadel Kassambara, Amelie Machura, Djamila Chemlal, Claire Gourzones, Guilhem Requirand, Nicolas Robert, Laure Vincent, Charles Herbaux, Angélique Bruyer, Jerome Moreaux

Blood (2021) 138 (Supplement 1): 2651.

https://doi.org/10.1182/blood-2021-148584

Published: 2021

Journal Articles

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

Charles Herbaux, Stéphanie Poulain, Damien Roos-Weil, Jacques-Olivier Bay, Yann Guillermin, Francois Lemonnier, Kamel Laribi, Sorin Visanica, Jerome Moreaux, Hugo Gonzalez, Maxime Jullien, Abderrazak El Yamani, Houria Debarri, Sophie Godet, Franck Morschhauser, Olivier Tournilhac, Matthew S. Davids, Loic Ysebaert

Blood (2021) 138 (Supplement 1): 1201.

https://doi.org/10.1182/blood-2021-149228

Published: 2021

Journal Articles

Exploiting Transcription-Replication Conflicts As a Novel Therapeutic Intervention in Multiple Myeloma

Laure Dutrieux, Yea-Lih Lin, Malik Lutzmann, Guilhem Requirand, Nicolas Robert, Laure Vincent, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Michel Cogne, Philippe Pasero, Jerome Moreaux

Blood (2021) 138 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2021-151530

Published: 2021

Journal Articles

The origin of preplasmablastic cells

Jerome Moreaux

Blood (2021) 137 (9): 1134–1135.

https://doi.org/10.1182/blood.2020009746

Published: 2021

Journal Articles

Targeting DNA Repair to Overcome Drug Resistance in Hodgkin Lymphoma

Julie Devin, PharmD, Quentin Denis, Caroline Bret, PhD PharmD, Jerome Moreaux, PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-142510

Published: 2020

Journal Articles

DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets

Ludovic Gabellier, MD, Caroline Bret, PhD PharmD, Guillaume Bossis, PhD, Guillaume Cartron, MD PhD, Jerome Moreaux, PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-137417

Published: 2020

NARROW

KDM6A controls immunogenicity in MM

Integrative single-cell chromatin and transcriptome analysis of human plasma cell differentiation

Integrative Multi-Omics Analysis of Tumor-Immune Microenvironment in Multiple Myeloma: Novel Insights and Therapeutic Implications

Integrative Single-Cell RNA-Seq and Single-Cell ATAC-Seq Analysis of Human Plasma Cell Differentiation

Epigenetic Modifiers MMSET and EZH2 Physically Interact and Cooperate to Support Multiple Myeloma Pathophysiology

Characterization of a New Metabolic Score Correlated with CD38 Cell-Surface Expression and Response to Daratumumab Treatment in Multiple Myeloma

Translation Inhibition through eIF4A1 Targeting in Multiple Myeloma Is a Promising Therapeutic Strategy

Lipid-Mediated Modulation of DNA Damage Signaling As a Prognostic and Therapeutic Strategy Against Multiple Myeloma

Early Progressions of Undetermined Significance (EPUS) in the Month Following CAR-T Cells for B-Cell NHL Is Mainly Related to Pseudoprogression

Ironomycin Induces Mantle Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Targeting Iron Homeostasis As a Therapeutic Strategy in Multiple Myeloma

EZH2 Targeting Induces CD38 Upregulation and Response to Anti-CD38 Antibodies in Multiple Myeloma

Development of a Robust BH3 Profiling Toolkit for Precision Medicine in Hematologic Malignancies

PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma

Genomic Characterization of in Vitro Acquired-Resistance to Proteasome Inhibitors

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

Exploiting Transcription-Replication Conflicts As a Novel Therapeutic Intervention in Multiple Myeloma

The origin of preplasmablastic cells

Targeting DNA Repair to Overcome Drug Resistance in Hodgkin Lymphoma

DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only